R Squared’s AbCellera Biologics ABCL Stock Holding History

R Squared’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-470	Closed	-$1.38K	–	293
2024 Q4	$1.38K	Buy	+470	New	+$1.31K	﹤0.01%	1498

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

R Squared's ABCL Position: Q1 2025 in Review

R Squared sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 470 shares — an estimated $1.38K sold.

R Squared first reported a position in ABCL in Q4 2024 and held it in 1 quarter. The position peaked at $1.38K in Q4 2024. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

R Squared reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
R Squared sold 470 AbCellera Biologics shares in Q1 2025, an estimated $1.38K.
R Squared first reported a position in AbCellera Biologics in Q4 2024 and held it in 1 quarter.
R Squared's AbCellera Biologics position peaked at $1.38K in Q4 2024.
129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.